Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
| Ultimovacs ASA: Annual Report 2023 | ||
| By: GlobeNewswire - 21 Mar 2024 | Back to overview list |
|
Oslo, 21 March 2024: Ultimovacs ASA (“Ultimovacs”, ticker ULTI), a clinical-stage biotechnology leader in novel immunotherapeutic cancer vaccines, announces that the Board of Directors of Ultimovacs ASA has approved the Annual Report and ESG Report for 2023. Please find a PDF version of the annual report, as well as the report in European Single Electronic Format (ESEF), as attachments to this release. The Annual Report is also available at the company's website: www.ultimovacs.com This information is subject to the disclosure requirements pursuant to Section 5-12 in the Norwegian Securities Trading Act. For further information, please see www.ultimovacs.com or contact: Jónas Einarsson, Chairman of the Board of Directors of Ultimovacs ASA Email: je@radforsk.no Phone: +47 480 96 355 Carlos de Sousa, CEO Email: carlos.desousa@ultimovacs.com Phone: +47 908 92507
Hans Vassgård Eid, CFO Email: hans.eid@ultimovacs.com Phone: +47 482 48632 Anne Worsøe, Head of Investor Relations & ESG Email: anne.worsoe@ultimovacs.com Phone: +47 90686815
Attachments 
|
||
|
||
 | Back to overview list | |